Develop and commercialize therapies for chronic and life-threatening diseases. Focus on pulmonary arterial hypertension (PAH) and related conditions. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 17% a year over the last 4 years. Every year shown ended in profit.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 17% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 42% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 17% a year on average.
There is $1.6B in the vault; even if every debt were paid off, $1.5B would remain.
Over the last 12 months, executives reported 2746 sells against just 316 buys. Not an alarm bell by itself, but a number worth watching.
Since the drop from its peak, buyer appetite hasn’t come back.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, UTHR sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: UTHR is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.